Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127763 · ClinicalTrials.gov registry record · Phase 2
RAD001 Plus Carboplatin in Breast Cancer Patients
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01127763 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 25 participants.
The verdict
NCT01127763, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study investigates the effectiveness of combination of carboplatin and investigational agent RAD001 in triple-negative breast cancer.
Interventions
- DRUG Carboplatin
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127763
The ClinicalTrials.gov registry entry for NCT01127763 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01127763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01127763 about?
NCT01127763 is a clinical study titled "RAD001 Plus Carboplatin in Breast Cancer Patients". This study investigates the effectiveness of combination of carboplatin and investigational agent RAD001 in triple-negative breast cancer.
What is the current status of trial NCT01127763?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2010-06. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01127763?
The interventions under investigation include: Carboplatin (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT01127763?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.